New Melanoma Vaccine Shows Promise in Clinical Trials

A new personalized melanoma vaccine, developed by Merck and Moderna, has shown encouraging results in reducing the risk of cancer recurrence or death when used alongside immunotherapy.

Early clinical trial data revealed that the vaccine, named intismeran, combined with existing immunotherapy treatments, lowered the likelihood of cancer returning or death by 42% compared to immunotherapy alone.

The approach targets specific genetic mutations in a patient’s tumor, tailoring the treatment to individual cancer profiles. This personalized strategy aims to enhance the immune system’s ability to recognize and attack cancer cells.

While the findings represent a significant step forward, researchers emphasize that further studies are needed to confirm long-term effectiveness and safety before the vaccine can be widely adopted.

Based on reporting from Medical Xpress (Cancer).

Source: Medical Xpress (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.